Affinity maturation and characterization of the ofatumumab monoclonal antibody

Publication year: 2018
Authors: Payandeh Z. 1, Rajabibazl M. 2,3, Mortazavi Y. 1,4, Rahimpour A. 3, Taromchi A.H. 1,4, Dastmalchi S. 5,6
Affiliations:

1 - Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2 - Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 - Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 - Cancer Gene Therapy Research Center, Department of Medical Biotechnology and Nanotechnology Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
5 - Biotechnology Research Center, Department of Medicinal chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
6 - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Near East University, Nicosia, North Cyprus, Mersin, Turkey

Published in: Journal of Cellular Biochemistry, 2018
doi: 10.1002/jcb.27457

CD20 molecule, a phosphoprotein with 297 amino acids and four transmembrane domains, is a member of MS4A protein family. Anti-CD20 antibodies such as ofatumumab, which have been developed for cancer treatment and has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. Rational engineering methods can be applied with reasonable success to improve functional characteristics of antibodies. Considering the importance of this issue, we have used in silico modeling approach for the improvement of ofatumumab monoclonal antibody. Four mutated variants of ofatumumab were developed and expressed in Chinese hamster ovary (CHO) cells along with the unmodified antibody. Analysis of affinity of the purified antibodies with CD20 showed significant improvement in antigen-binding characteristics of one of the variants compared with the control antibody. This study represents the first step toward development of the second generation ofatumumab antibody with improved affinity.


MP-SPR keywords: affinity, antibody variants, binding constants, cancer treatment, kinetics, molecular interactions analysis, ofatumumab, protein-antibody interaction